Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular (CV) outcomes in patients with or without Type 2 diabetes and heart failure (HF). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.